Lucid Diagnostics Inc.
LUCDLucid Diagnostics Inc. in brief
Lucid Diagnostics Inc. is a listed company in the Healthcare sector, based in New York, New York, USA. Its market value was $89 M on 30 October 2026, which makes it the 19,162nd largest listed company in the world and the 3,576th largest in the USA on this site. In the year to December 2025 it had sales of $5 M and a net loss of $58 M. It employs about 82 people and Lishan Aklog is its chief executive. Its shares trade under the symbol LUCD (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Lucid Diagnostics Inc.
Lucid Diagnostics is a commercial-stage cancer prevention medical diagnostics technology company. Lucid is focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.
We believe that our flagship product, the EsoGuard Esophageal DNA Test, performed on samples collected with the EsoCheck Esophageal Cell Collection Device, constitutes the first and only commercially available diagnostic test capable of serving as a widespread testing tool with the goal of preventing EAC deaths, through early detection of esophageal precancer in at-risk GERD patients.
From the company's annual report filed with the US SEC: read the report
Lucid Diagnostics Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 15 October 2021; shares registered for exchange trading on 12 October 2021.
- 2025
- 💰Record revenue of $5 millionFY2025, the highest of the 5 years on record.
Events of Lucid Diagnostics Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,006 (Jan 2022) · #4,712 (Dec 2022) · #4,642 (Jul 2023) · #3,955 (Jan 2024) · #1,723 (Mar 2026) · #3,115 (Aug 2026) · #3,367 (Oct 2026) · #3,580 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 16.4×
- Price / book
- 8.1×
- Free cash flow yield
- -52.4%
- Net margin (TTM)
- -892.3%
- Operating margin
- -1053.9%
- Return on equity
- -443.7%
- Liabilities / assets
- 73.0%
- Revenue growth
- +8.3%
- R&D / revenue
- 120.6%
- Revenue per employee
- $57 K
- Profit per employee
- $-707 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $5M | +8.3% | $-50M | $-58M | -1231.6% |
| Dec 2024 | $4M | +79.0% | $-46M | $-46M | -1046.7% |
| Dec 2023 | $2M | +539.5% | $-48M | $-53M | -2167.5% |
| Dec 2022 | $0M | -24.0% | $-56M | $-56M | -14781.6% |
| Dec 2021 | $1M | — | $-27M | $-28M | -5616.0% |
| Dec 2020 | — | — | $-8M | $-8M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-46M | $0M | $-47M | — | — |
| Dec 2024 | $-44M | $0M | $-44M | $-1.05 | — |
| Dec 2023 | $-33M | — | — | $-1.26 | — |
| Dec 2022 | $-30M | $3M | $-33M | $-1.55 | — |
| Dec 2021 | $-18M | $1M | $-19M | $-1.51 | — |
| Dec 2020 | $-6M | — | — | $-0.59 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (-0.8% on a year earlier), net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Oct 22, 20268-KCurrent reportUnregistered share sale · Bylaws amended
- Oct 16, 20268-KCurrent reportListing notice
- Sep 22, 20268-KCurrent reportRegulation FD disclosure
- Aug 13, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Jun 24, 20268-KCurrent reportBylaws amended · Shareholder vote
- May 14, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- May 13, 202610-QQuarterly report · period to Mar 2026
- Apr 30, 2026DEF 14AProxy statement
- Apr 24, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Lucid Diagnostics Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $5 M
- Operating income
- $-50 M
- Net income
- $-58 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $40 M
- Total liabilities
- $30 M
- Total equity
- $11 M
As of December-2025
Top 100 institutional investors in Lucid Diagnostics Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8,387,879 | +14,762 (+0.18%) | 4.05% | $6 M | Nov 13, 2026 |
| 2 | Alyeska Investment Group, L.P. | 7,970,115 | -886,729 (-10.01%) | 3.85% | $6 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 6,045,227 | -511,117 (-7.80%) | 2.92% | $5 M | Nov 13, 2026 |
| 4 | Two Seas Capital LP | 6,000,000 | 0 (0.00%) | 2.90% | $5 M | Oct 6, 2026 |
| 5 | Aberdeen Group plc | 4,419,935 | +596,938 (+15.61%) | 2.14% | $3 M | Nov 10, 2026 |
| 6 | Masters Capital Management LLC | 4,000,000 | 0 (0.00%) | 1.93% | $3 M | Nov 16, 2026 |
| 7 | Geode Capital Management, LLC | 3,566,004 | -223,944 (-5.91%) | 1.72% | $3 M | Nov 6, 2026 |
| 8 | Wells Fargo & Company/mn | 2,535,899 | +468,853 (+22.68%) | 1.23% | $2 M | Nov 16, 2026 |
| 9 | State Street Corp | 2,442,220 | +4,883 (+0.20%) | 1.18% | $2 M | Nov 12, 2026 |
| 10 | First Manhattan Co. LLC. | 2,188,550 | 0 (0.00%) | 1.06% | $2 M | Nov 16, 2026 |
| 11 | Northern Trust Corp | 1,236,016 | +16,137 (+1.32%) | 0.60% | $1 M | Nov 16, 2026 |
| 12 | UBS Group AG | 1,144,954 | +299,640 (+35.45%) | 0.55% | $1 M | Nov 10, 2026 |
| 13 | Perkins Capital Management Inc | 1,125,000 | 0 (0.00%) | 0.54% | $1 M | Nov 2, 2026 |
| 14 | Vanguard Portfolio Management LLC | 1,066,566 | +44,304 (+4.33%) | 0.52% | $1 M | Nov 13, 2026 |
| 15 | Vanguard Fiduciary Trust Co | 1,002,094 | -66,015 (-6.18%) | 0.48% | $1 M | Nov 13, 2026 |
| 16 | Citadel Advisors LLC | 644,559 | +608,197 (+1672.62%) | 0.31% | $0 M | Nov 16, 2026 |
| 17 | Raymond James Financial Inc | 577,381 | 0 (0.00%) | 0.28% | $0 M | Nov 12, 2026 |
| 18 | Lido Advisors, LLC | 446,711 | -28 (-0.01%) | 0.22% | $0 M | Nov 4, 2026 |
| 19 | Charles Schwab Investment Management Inc | 407,000 | +81,688 (+25.11%) | 0.20% | $0 M | Nov 16, 2026 |
| 20 | Rothschild Capital Partners, LLC | 372,340 | New | 0.18% | $0 M | Nov 16, 2026 |
| 21 | XTX Topco Ltd | 342,566 | New | 0.17% | $0 M | Nov 16, 2026 |
| 22 | XML Financial, LLC | 323,195 | 0 (0.00%) | 0.16% | $0 M | Oct 29, 2026 |
| 23 | Bank of New York Mellon Corp | 313,474 | +11,771 (+3.90%) | 0.15% | $0 M | Nov 5, 2026 |
| 24 | Nuveen, LLC | 301,157 | +106,092 (+54.39%) | 0.15% | $0 M | Nov 10, 2026 |
| 25 | Bank Of Montreal /can/ | 289,936 | 0 (0.00%) | 0.14% | $0 M | Nov 9, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Focus Partners Wealth | 183,708 | +35,003 (+23.54%) | 0.09% | $0 M | Nov 12, 2026 |
| 27 | Tripletail Wealth Management, LLC | 183,417 | 0 (0.00%) | 0.09% | $0 M | Nov 16, 2026 |
| 28 | Squarepoint Ops LLC | 169,704 | New | 0.08% | $0 M | Nov 9, 2026 |
| 29 | Bank Of America Corp /de/ | 162,450 | +65,674 (+67.86%) | 0.08% | $0 M | Nov 16, 2026 |
| 30 | Morgan Stanley | 142,094 | +76,351 (+116.14%) | 0.07% | $0 M | Nov 13, 2026 |
| 31 | Rhumbline Advisers | 140,891 | +56,808 (+67.56%) | 0.07% | $0 M | Nov 10, 2026 |
| 32 | Deutsche Bank AG\ | 129,876 | -18,185 (-12.28%) | 0.06% | $0 M | Nov 6, 2026 |
| 33 | LPL Financial LLC | 129,443 | -3,712 (-2.79%) | 0.06% | $0 M | Nov 6, 2026 |
| 34 | Price T Rowe Associates Inc /MD/ | 121,952 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 35 | AQR Capital Management LLC | 119,525 | -603,675 (-83.47%) | 0.06% | $0 M | Nov 16, 2026 |
| 36 | Invesco Ltd. | 92,610 | +9,856 (+11.91%) | 0.04% | $0 M | Nov 12, 2026 |
| 37 | Sequoia Financial Advisors, LLC | 92,140 | -10 (-0.01%) | 0.04% | $0 M | Nov 13, 2026 |
| 38 | Jpmorgan Chase & Co | 74,382 | +11,607 (+18.49%) | 0.04% | $0 M | Nov 12, 2026 |
| 39 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 72,152 | +3,681 (+5.38%) | 0.03% | $0 M | Nov 16, 2026 |
| 40 | Corient Private Wealth LP | 64,501 | +54,473 (+543.21%) | 0.03% | $0 M | Nov 16, 2026 |
| 41 | Barclays PLC | 61,773 | +35,183 (+132.32%) | 0.03% | $0 M | Nov 6, 2026 |
| 42 | New York State Common Retirement Fund | 58,700 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 43 | Traphagen Investment Advisors LLC | 58,590 | 0 (0.00%) | 0.03% | $0 M | Oct 14, 2026 |
| 44 | Virtu Financial LLC | 56,249 | New | 0.03% | $0 M | Nov 17, 2026 |
| 45 | Susquehanna International Group, LLP | 53,881 | +37,763 (+234.29%) | 0.03% | $0 M | Nov 16, 2026 |
| 46 | MML Investors Services, LLC | 50,000 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 47 | Alliancebernstein L.P. | 47,200 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 48 | Sargent Investment Group, LLC | 45,000 | -20,000 (-30.77%) | 0.02% | $0 M | Nov 13, 2026 |
| 49 | Royal Bank Of Canada | 44,607 | +20,170 (+82.54%) | 0.02% | $0 M | Nov 16, 2026 |
| 50 | Magnus Financial Group LLC | 40,900 | -14,500 (-26.17%) | 0.02% | $0 M | Oct 21, 2026 |
| 51 | Vanguard Global Advisers, LLC | 40,457 | +15,557 (+62.48%) | 0.02% | $0 M | Nov 13, 2026 |
| 52 | Oppenheimer & Co Inc | 40,000 | +10,000 (+33.33%) | 0.02% | $0 M | Oct 26, 2026 |
| 53 | StoneX Group Inc. | 39,748 | New | 0.02% | $0 M | Nov 3, 2026 |
| 54 | BNP Paribas Financial Markets | 37,539 | +14,914 (+65.92%) | 0.02% | $0 M | Nov 12, 2026 |
| 55 | Pine Valley Investments Ltd Liability Co | 36,483 | 0 (0.00%) | 0.02% | $0 M | Nov 9, 2026 |
| 56 | Russell Investments Group, Ltd. | 36,355 | -1,615,433 (-97.80%) | 0.02% | $0 M | Nov 6, 2026 |
| 57 | R Squared Ltd | 34,341 | +3,754 (+12.27%) | 0.02% | $0 M | Nov 6, 2026 |
| 58 | Police & Firemen's Retirement System of New Jersey | 30,739 | 0 (0.00%) | 0.01% | $0 M | Nov 9, 2026 |
| 59 | Americana Partners, LLC | 26,427 | 0 (0.00%) | 0.01% | $0 M | Oct 28, 2026 |
| 60 | Sax Wealth Advisors, LLC | 25,287 | New | 0.01% | $0 M | Oct 13, 2026 |
| 61 | Two Sigma Securities, LLC | 22,854 | -17,067 (-42.75%) | 0.01% | $0 M | Nov 16, 2026 |
| 62 | Prudential Financial Inc | 22,435 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 63 | Scratch Capital LLC | 20,994 | 0 (0.00%) | 0.01% | $0 M | Nov 2, 2026 |
| 64 | Gabelli Funds LLC | 19,500 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 65 | ProShare Advisors LLC | 19,417 | -51 (-0.26%) | 0.01% | $0 M | Oct 29, 2026 |
| 66 | Victory Capital Management Inc | 18,294 | +547 (+3.08%) | 0.01% | $0 M | Nov 10, 2026 |
| 67 | Axxcess Wealth Management, LLC | 18,254 | New | 0.01% | $0 M | Oct 21, 2026 |
| 68 | Principal Financial Group Inc | 18,154 | +6,769 (+59.46%) | 0.01% | $0 M | Nov 2, 2026 |
| 69 | Osaic Holdings, Inc. | 17,292 | -5,000 (-22.43%) | 0.01% | $0 M | Nov 12, 2026 |
| 70 | CIBC Bancorp USA Inc. | 15,289 | New | 0.01% | $0 M | Nov 13, 2026 |
| 71 | Legal & General Group Plc | 14,580 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 72 | Accordant Advisory Group Inc | 14,300 | 0 (0.00%) | 0.01% | $0 M | Oct 29, 2026 |
| 73 | Crux Wealth Advisors | 14,250 | New | 0.01% | $0 M | Nov 10, 2026 |
| 74 | Tower Research Capital LLC (TRC) | 14,222 | -5,489 (-27.85%) | 0.01% | $0 M | Nov 16, 2026 |
| 75 | Centiva Capital, LP | 14,156 | -95,284 (-87.07%) | 0.01% | $0 M | Nov 13, 2026 |
| 76 | Goldman Sachs Group Inc | 13,970 | -56,641 (-80.22%) | 0.01% | $0 M | Nov 16, 2026 |
| 77 | Xponance LLC | 13,913 | -246 (-1.74%) | 0.01% | $0 M | Nov 3, 2026 |
| 78 | One Wealth Management Investment & Advisory Services, LLC | 13,688 | New | 0.01% | $0 M | Nov 16, 2026 |
| 79 | Creative Planning | 13,334 | -7,734 (-36.71%) | 0.01% | $0 M | Nov 2, 2026 |
| 80 | Obermeyer Wealth Partners | 13,000 | 0 (0.00%) | 0.01% | $0 M | Oct 21, 2026 |
| 81 | AlphaCore Capital LLC | 12,380 | +2,205 (+21.67%) | 0.01% | $0 M | Nov 4, 2026 |
| 82 | Ausdal Financial Partners, Inc. | 12,075 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 83 | Anchyra Partners LLC | 11,589 | New | 0.01% | $0 M | Oct 13, 2026 |
| 84 | Waterloo Capital, L.P. | 11,484 | New | 0.01% | $0 M | Nov 16, 2026 |
| 85 | Ieq Capital, LLC | 10,281 | -85,262 (-89.24%) | 0.01% | $0 M | Nov 10, 2026 |
| 86 | HighTower Advisors, LLC | 10,012 | New | 0.00% | $0 M | Nov 10, 2026 |
| 87 | Beacon Pointe Advisors, LLC | 10,000 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 88 | Farther Finance Advisors, LLC | 9,167 | +8,926 (+3703.73%) | 0.00% | $0 M | Oct 8, 2026 |
| 89 | Citigroup Inc | 7,660 | -62,133 (-89.02%) | 0.00% | $0 M | Nov 4, 2026 |
| 90 | Ameritas Investment Partners, Inc. | 7,067 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 91 | Sterling Capital Management LLC | 4,877 | +4,355 (+834.29%) | 0.00% | $0 M | Oct 22, 2026 |
| 92 | FMR LLC | 2,605 | -1,610 (-38.20%) | 0.00% | $0 M | Nov 10, 2026 |
| 93 | Optiver Holding B.V. | 1,436 | New | 0.00% | $0 M | Nov 16, 2026 |
| 94 | California State Teachers Retirement System | 1,263 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 95 | Arax Advisory Partners | 1,169 | -8,824 (-88.30%) | 0.00% | $0 M | Nov 12, 2026 |
| 96 | Jones Financial Companies Lllp | 1,010 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 97 | Winch Advisory Services, LLC | 800 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 98 | Robinhood Markets, Inc. | 500 | — | 0.00% | $0 M | Nov 18, 2026 |
| 99 | GAMMA Investing LLC | 467 | +325 (+228.87%) | 0.00% | $0 M | Oct 8, 2026 |
| 100 | Quaker Wealth Management, LLC | 390 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding Lucid Diagnostics Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 4.55 M | $5 M | 2.2% | <0.01% | +50% | Jun 30, 2026 |
| 🇺🇸 abrdn Healthcare Opportunities Fundabrdn Inc. | 3.82 M | $4 M | 1.8% | 0.50% | +4.9% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 3.57 M | $4 M | 1.7% | <0.01% | +62% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.86 M | $2 M | 0.90% | <0.01% | +78% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors | 1.40 M | $1 M | 0.67% | <0.01% | +291% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.58 M | $1 M | 0.76% | <0.01% | +80% | Jul 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 497,964 | $1 M | 0.24% | 0.04% | +119% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 507,380 | $1 M | 0.25% | <0.01% | +1.7% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 459,876 | $0 M | 0.22% | <0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 362,863 | $0 M | 0.18% | <0.01% | +84% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 277,964 | $0 M | 0.13% | <0.01% | +132% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 171,254 | $0 M | 0.08% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 195,065 | $0 M | 0.09% | <0.01% | +116% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 154,902 | $0 M | 0.07% | <0.01% | +109% | Jun 30, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 186,569 | $0 M | 0.09% | 0.02% | −71% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC | 138,850 | $0 M | 0.07% | 0.06% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC | 138,777 | $0 M | 0.07% | <0.01% | +362% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 140,008 | $0 M | 0.07% | <0.01% | +8.2% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 113,100 | $0 M | 0.05% | <0.01% | +104% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 91,840 | $0 M | 0.04% | <0.01% | +227% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 77,421 | $0 M | 0.04% | <0.01% | +59% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 77,112 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 64,276 | $0 M | 0.03% | 0.04% | — | Mar 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 71,030 | $0 M | 0.03% | <0.01% | +79% | Jul 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 56,088 | $0 M | 0.03% | <0.01% | +1.5% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 43,087 | $0 M | 0.02% | <0.01% | +153% | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 39,200 | $0 M | 0.02% | <0.01% | +54% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 39,786 | $0 M | 0.02% | <0.01% | +4.7% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 35,295 | $0 M | 0.02% | <0.01% | +3.2% | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 33,425 | $0 M | 0.02% | 0.02% | +100% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 33,747 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 32,030 | $0 M | 0.02% | <0.01% | +112% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 31,185 | $0 M | 0.02% | <0.01% | +158% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 23,600 | $0 M | 0.01% | <0.01% | +113% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 23,600 | $0 M | 0.01% | <0.01% | +113% | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 23,419 | $0 M | 0.01% | <0.01% | +83% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 22,417 | $0 M | 0.01% | <0.01% | +45% | Jun 30, 2026 |
| 🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 22,163 | $0 M | 0.01% | <0.01% | +309% | Jun 30, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 20,448 | $0 M | <0.01% | <0.01% | +149% | Jun 30, 2026 |
| 🇺🇸 Gabelli Healthcare & WellnessRx TrustGabelli Funds, LLC | 19,500 | $0 M | <0.01% | 0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 18,791 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 17,747 | $0 M | <0.01% | <0.01% | +75% | Jul 31, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 17,413 | $0 M | <0.01% | <0.01% | +121% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC | 13,521 | $0 M | <0.01% | <0.01% | +558% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 11,891 | $0 M | <0.01% | <0.01% | +107% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 13,939 | $0 M | <0.01% | <0.01% | +135% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 9,709 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC | 11,385 | $0 M | <0.01% | <0.01% | +439% | Jul 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 9,222 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 7,067 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 5,596 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 4,241 | $0 M | <0.01% | <0.01% | +8.6% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 3,835 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 3,357 | $0 M | <0.01% | <0.01% | −40% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 3,317 | $0 M | <0.01% | <0.01% | −41% | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 2,755 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 2,141 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 218 | $0 M | <0.01% | <0.01% | +16% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 58 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Lucid Diagnostics Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Dennis MatheisDirector | Buy | +245,000 | $1.000 | $245 K | 1.03 M | Form 4 |
| filed | Dennis MatheisDirector | Grant or award | +123,000 | — | — | 788,443 | Form 4 |
| filed | Michael Adam GordonGeneral Counsel and Secretary | Grant or award | +300,000 | — | — | 1.00 M | Form 4 |
| filed | Stanley LapidusDirector | Grant or award10b5-1 plan | +123,000 | — | — | 337,392 | Form 4 |
| filed | Shaun O'NeilPresident and COO | Grant or award | +620,000 | — | — | 1.45 M | Form 4 |
| filed | Jacque J. SokolovDirector | Grant or award | +123,000 | — | — | 320,460 | Form 4 |
| filed | Dennis M. McGrathChief Financial Officer | Grant or award | +470,000 | — | — | 1.81 M | Form 4 |
| filed | Debra WhiteDirector | Grant or award | +123,000 | — | — | 235,800 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Lucid Diagnostics Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 6,610 shares at $0.43
- : 443,755 shares at $0.41
- : 703,786 shares at $0.33
- : 819,993 shares at $0.33
- : 1.0 M shares at $0.35
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Lucid Diagnostics Inc. scorecard#
Passes 4 of the 15 checks that could be worked out: strongest in growth (3 of 4), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median8.1×Price to book 8.1× against Healthcare's median of 3.1×.
- ✗Price to sales below its peers' median16.4×Price to sales 16.4× against Healthcare's median of 3.8×.
- ✗Free cash flow yield above 5%-52.5%Free cash flow is -52.5% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 4
- ✓Revenue grew in the newest year8.3%Revenue up 8.3% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years131.4%131.4% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median131.4%131.4% a year against Healthcare's median of 8.5% (549 companies).
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$58 M-$58 M in fiscal 2025 against -$8 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$58 MNet income -$58 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-710.5%-710.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.3×Current ratio 1.31 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-11.36Z-score -11.36 (distress zone) for fiscal 2025.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Lucid Diagnostics Inc.'s statements, beside the median of Healthcare.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Return on equity | -710.5% | -36.9% | |
| Revenue growth, 3 years a year | 131.4% | 8.5% | |
| Revenue growth | 8.3% | 10.2% | |
| Free cash flow margin | -991.1% | -1.3% |
4of 8on the Piotroski tests of financial strength
- Net loss of $58 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$47 million.
- Receivables grew 1500% while revenue grew 8%: customers are paying later, or sales were booked ahead of cash.
- Revenue has grown 3 years in a row.
Lucid Diagnostics Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 4.7+8.3%100% | 4.3+79.0%100% | 2.4+544%100% | 0.4−24.6%100% | 0.5—100% | — | |
| Cost of revenue | 6.7−6.0%142% | 7.1—163% | — | 100+16994%26525% | 0.6—117% | — | |
| Gross profit | — | — | — | 0.4−24.6%100% | 0.5r−0.1—100% | — | |
| Research and development | 5.7−5.2%121% | 6.0−17.4%138% | 7.3−35.6%299% | 11r11+21.1%2986% | 9.3+70.8%1859% | 5.4—— | |
| Selling, general and administrative | — | — | — | — | 0.0+200%4.2% | 0.0—— | |
| Selling and marketing | 18+7.6%376% | 16+0.4%379% | 16+1.7%676% | 16+207%4280% | 5.3+303%1052% | 1.3—— | |
| General and administrative | 24+18.4%507% | 20+4.7%464% | 19−19.7%793% | 24r24+87.6%6359% | 13+734%2556% | 1.5—— | |
| Operating expenses | — | 50−1.0%1160% | 51−10.1%2097% | 57r57+103%15021% | 28r27+237%5584% | 8.3—— | |
| Total costs and expenses | 54+7.8%1155% | 50—1160% | — | — | — | — | |
| Operating income | −50—−1055% | −46—−1060% | −48—−1997% | −56r−56—−14921% | −27—−5484% | −8.3—— | |
| Interest and finance income | 0.4+19.9%8.2% | 0.3—7.4% | — | — | — | — | |
| Interest expense and finance costs | 0.0−15.4%0.5% | 0.0−93.8%0.6% | 0.4+5100%17.1% | 0.0−98.8%2.1% | 0.7—132% | — | |
| Other non-operating income (expense) | −8.4−1700%−178% | 0.5—12.0% | −4.2−5330%−172% | 0.1—21.2% | −0.7—−132% | — | |
| Income before tax | −58—−1233% | −46—−1048% | −53—−2169% | −56—−14899% | −28—−5616% | −8.3—— | |
| Income tax | 0—0.0% | 0—0.0% | — | — | — | — | |
| Net income attributable to shareholders | −58—−1233% | −46—−1048% | −53—−2169% | −56—−14899% | −28—−5616% | −8.3—— | |
| Earnings per share, basic | -0.69—— | -1.05—— | -1.26—— | -1.55—— | -1.51—— | -0.59—— | |
| Earnings per share, diluted | — | -1.05—— | -1.26—— | -1.55—— | -1.51—— | -0.59—— | |
| Shares, weighted average (basic) | 102+102%— | 51+21.0%— | 42+15.4%— | 36+94.4%— | 19—— | — | |
| Shares, weighted average (diluted) | — | 51+21.0%— | 42+15.4%— | 36+94.4%— | 19+31.8%— | 14—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 35+55.2%85.8% | 22+18.3%72.8% | 19−15.9%69.3% | 22−58.1%69.1% | 54+48239%90.9% | 0.1r0.1—5.1% | |
| Receivables | 0.6+1329%1.6% | 0.00.0%0.1% | 0.0+165%0.2% | 0.0−91.5%0.1% | 0.2—0.3% | — | |
| Inventory | 0.4+3.5%0.9% | 0.3+22.7%1.1% | 0.3+150%1.0% | 0.1—0.3% | — | — | |
| Other current assets | 1.8−26.5%4.4% | 2.4−15.8%7.8% | 2.9+62.7%10.5% | 1.8r1.9−49.1%5.4% | 3.4+159%5.8% | 1.3r1.3—60.5% | |
| Current assets | 37+49.0%92.6% | 25+13.9%81.9% | 22−9.4%80.9% | 24−57.5%74.9% | 57+3879%97.1% | 1.4r1.4—65.6% | |
| Property, plant and equipment | 0.8−23.8%2.0% | 1.1−20.4%3.5% | 1.3−16.2%4.9% | 1.6+64.0%4.9% | 1.0—1.6% | — | |
| Right-of-use (leased) assets | 1.8−31.5%4.5% | 2.6+102%8.6% | 1.3−34.9%4.8% | 2.0—6.2% | — | — | |
| Other intangible assets | 0.3−57.2%0.8% | 0.7−48.3%2.4% | 1.4−58.7%5.2% | 3.4—10.6% | — | — | |
| Total assets | 40+31.7%100% | 31+12.6%100% | 27−16.1%100% | 33−44.9%100% | 59+2588%100% | 2.2r2.2—100% | |
| Accounts payable | 1.0−21.8%2.4% | 1.2+8.3%4.0% | 1.1+8.5%4.2% | 1.1−29.1%3.2% | 1.5−27.6%2.5% | 2.1r2.1—93.8% | |
| Current liabilities | 29+21.5%70.7% | 24−19.9%76.6% | 29+249%108% | 8.4+97.8%25.9% | 4.3—7.2% | — | |
| Lease liabilities (non-current) | 0.9−48.5%2.3% | 1.8+805%5.9% | 0.2−80.8%0.7% | 1.0—3.2% | — | — | |
| Total liabilities | 30+16.5%73.0% | 25−14.4%82.4% | 30+213%108% | 9.5+122%29.1% | 4.3−72.9%7.2% | 16r16—716% | |
| Retained earnings | −274—−678% | −204—−663% | −151—−553% | −98—−302% | −42—−71.0% | −14r−14—−630% | |
| Shareholders' equity | 11+103%27.0% | 5.4—17.6% | −2.3−110%−8.5% | 23−57.9%70.9% | 55—92.8% | −14r−14—−616% | |
| Total liabilities and equity | 40+31.7%100% | 31+12.6%100% | 27−16.1%100% | 33−44.9%100% | 59+2588%100% | 2.2r2.2—100% | |
| Shares outstanding | 131+108%— | 63+49.0%— | 42+4.5%— | 41+16.0%— | 35+147%— | 14—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.9−25.3%18.5% | 1.2−53.3%26.9% | 2.5+29.1%103% | 1.9+48300%514% | 0.0—0.8% | — | |
| Share-based compensation | 4.5+7.4%95.4% | 4.2−27.4%96.2% | 5.8−58.4%237% | 14+51.7%3676% | 9.1r9.6+13952%1827% | 0.1—— | |
| Cash from operating activities | −46—−988% | −44—−1016% | −33—−1352% | −30—−7874% | −18—−3534% | −5.6—— | |
| Capital expenditure | −0.2—−4.2% | −0.3—−6.8% | — | −3.2—−849% | −0.9—−172% | — | |
| Intangible assets bought | — | −0.4—−8.1% | — | — | — | — | |
| Cash from investing activities | −0.2—−4.2% | −0.6—−14.9% | −0.2—−9.1% | −4.1—−1090% | −0.9—−172% | — | |
| Debt issued | — | — | — | — | — | 7.9—— | |
| Debt repaid | — | −2.7—−61.1% | — | — | — | — | |
| Shares issued | — | — | — | 1.8—479% | — | — | |
| Cash from financing activities | 59+22.3%1254% | 48+63.8%1110% | 29+1028%1213% | 2.6−96.4%693% | 72+1191%14415% | 5.6—— | |
| Change in cash | 12+257%262% | 3.5—79.7% | −3.6—−147% | −31−158%−8271% | 54—10709% | −0.0—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 5.4+23.6%100% | 1.2−0.7%100% | 1.5+26.7%100% | 1.3+51.7%100% | 1.5*+25.6%100% | 1.2+3.3%100% | 1.2+19.2%100% | 0.8−17.3%100% | 1.2*+15.1%100% | 1.2—100% | 1.0—100% | 1.0—100% | 1.0*—100% | |
| Cost of revenue | 6.3—116% | 1.4−17.3%117% | 1.4−7.5%98.0% | 1.6+4.8%129% | 1.9*—124% | 1.7—140% | 1.6—134% | 1.6—187% | — | — | — | — | — | |
| Research and development | 5.3−1.9%97.5% | 1.2−7.1%98.3% | 1.2−5.0%80.9% | 1.2−15.5%96.0% | 1.7*+18.6%115% | 1.3−23.6%105% | 1.3−8.5%108% | 1.4−4.9%172% | 1.5*−24.2%121% | 1.7—142% | 1.4—141% | 1.5—150% | 1.9*—184% | |
| Selling and marketing | 21+30.6%393% | 5.3+22.4%437% | 5.8+44.1%392% | 5.0+22.9%398% | 5.3*+33.4%355% | 4.3+5.8%354% | 4.0−4.8%345% | 4.1−3.0%491% | 4.0*−9.2%335% | 4.1—346% | 4.2—431% | 4.2—419% | 4.4*—424% | |
| General and administrative | 23−0.2%427% | 5.5−1.2%460% | 5.8+2.5%391% | 5.4−11.8%432% | 6.5*+10.6%431% | 5.6+4.7%463% | 5.6+15.4%483% | 6.2+51.4%744% | 5.9*+39.5%490% | 5.4—457% | 4.9—499% | 4.1—407% | 4.2*—404% | |
| Operating expenses | — | — | — | — | — | 13+0.8%1071% | 13+3.1%1079% | 13+12.9%1608% | 14*+8.6%1134% | 13—1098% | 12—1247% | 12—1178% | 12*—1201% | |
| Total costs and expenses | 57—1042% | 13+3.9%1120% | 14+13.8%968% | 13+0.4%1064% | 16*—1032% | 13—1071% | 13—1079% | 13—1608% | — | — | — | — | — | |
| Operating income | −51—−942% | −12—−1020% | −13—−868% | −12—−964% | −14*—−932% | −12—−971% | −11—−979% | −12—−1508% | −12*—−1034% | −12—−998% | −11—−1147% | −11—−1078% | −11*—−1101% | |
| Interest and finance income | 0.3—5.8% | 0.1−41.6%4.9% | 0.1−30.0%5.2% | 0.1+6.1%5.6% | 0.1*—7.3% | 0.1—8.3% | 0.1—9.5% | 0.1—8.0% | — | — | — | — | — | |
| Interest expense and finance costs | 0.0−29.2%0.3% | 0.0−50.0%0.1% | 0.0−33.3%0.3% | 0.0−33.3%0.5% | 0.0*−14.3%0.4% | 0.0+100%0.2% | 0.00.0%0.5% | 0.0−25.0%1.1% | 0.0*−36.4%0.6% | 0.0—0.1% | 0.0—0.6% | 0.0—1.2% | 0.0*—1.1% | |
| Other non-operating income (expense) | 2.7—49.0% | 5.6+311%465% | 1.1−84.0%75.6% | −1.8—−143% | −2.3*−370%−150% | 1.4—112% | 6.9+3614%597% | −14−8112%−1742% | 0.8*+33.9%69.7% | −0.7—−57.8% | 0.2—19.2% | 0.2—18.0% | 0.6*—59.9% | |
| Income before tax | −49—−893% | −6.7—−555% | −12—−793% | −14—−1107% | −16*—−1082% | −10—−859% | −4.4—−382% | −27—−3250% | −12*—−964% | −12—−1056% | −11—−1128% | −11—−1060% | −11*—−1041% | |
| Income tax | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0*—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | — | — | — | — | — | |
| Net income attributable to shareholders | −49—−893% | −6.7—−555% | −12—−793% | −14—−1107% | −16*—−1082% | −10—−859% | −4.4—−382% | −27—−3250% | −12*—−964% | −12—−1056% | −11—−1128% | −11—−1060% | −11*—−1041% | |
| Earnings per share, basic | — | -0.03—— | -0.08—— | -0.17—— | — | -0.10—— | -0.08—— | -0.52—— | — | -0.25—— | -0.23—— | -0.40—— | — | |
| Earnings per share, diluted | — | — | — | — | — | -0.10—— | -0.08—— | -0.52—— | — | -0.25—— | -0.23—— | -0.40—— | — | |
| Shares, weighted average (basic) | 191+76.5%— | 191+76.5%— | 183+85.0%— | 140+104%— | — | 108+115%— | 99+105%— | 69+52.8%— | — | 50—— | 48—— | 45—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | 108+115%— | 99+105%— | 69+52.8%— | — | 50—— | 48—— | 45—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 18—64.6% | 18−62.0%64.6% | 33+7.3%85.8% | 28+10.5%81.8% | 35+55.2%85.8% | 47+227%89.0% | 31+24.9%80.5% | 25+1.9%77.0% | 22+18.3%72.8% | 14—64.1% | 25—73.1% | 25—77.3% | 19—69.3% | |
| Receivables | 0.8—3.0% | 0.8+53.3%3.0% | 1.1+192%2.8% | 0.7+1030%2.0% | 0.6+1329%1.6% | 0.6+1310%1.0% | 0.4+133%1.0% | 0.1+24.5%0.2% | 0.00.0%0.1% | 0.0—0.2% | 0.2—0.5% | 0.0—0.2% | 0.0—0.2% | |
| Inventory | 0.5—1.9% | 0.5+7.0%1.9% | 0.5−4.2%1.2% | 0.5−3.1%1.4% | 0.4+3.5%0.9% | 0.5−25.3%0.9% | 0.5−26.1%1.3% | 0.5+18.0%1.5% | 0.3+22.7%1.1% | 0.7—2.9% | 0.7—2.0% | 0.4—1.3% | 0.3—1.0% | |
| Other current assets | 1.4—4.9% | 1.4−7.8%4.9% | 1.6−10.1%4.2% | 2.3+32.7%6.8% | 1.8−26.5%4.4% | 1.5−10.4%2.8% | 1.8−16.1%4.7% | 1.8−25.5%5.3% | 2.4−15.8%7.8% | 1.6—7.3% | 2.2—6.4% | 2.4—7.3% | 2.9—10.5% | |
| Current assets | 26—93.2% | 26−47.9%93.2% | 37+8.2%94.0% | 31+13.9%92.0% | 37+49.0%92.6% | 50+196%93.7% | 34+21.1%87.5% | 28−0.2%84.0% | 25+13.9%81.9% | 17—74.4% | 28—81.9% | 28—86.1% | 22—80.9% | |
| Property, plant and equipment | 0.7—2.5% | 0.7−18.1%2.5% | 0.8−14.6%2.1% | 0.9−12.8%2.7% | 0.8−23.8%2.0% | 0.9−8.3%1.6% | 0.9−9.7%2.5% | 1.0−16.3%3.2% | 1.1−20.4%3.5% | 0.9—4.2% | 1.1—3.1% | 1.2—3.9% | 1.3—4.9% | |
| Right-of-use (leased) assets | 1.2—4.2% | 1.2−41.8%4.2% | 1.4−37.5%3.6% | 1.6−35.2%4.7% | 1.8−31.5%4.5% | 2.0−29.3%3.8% | 2.2−26.3%5.8% | 2.5+136%7.5% | 2.6+102%8.6% | 2.9—12.7% | 3.0—8.9% | 1.0—3.2% | 1.3—4.8% | |
| Other intangible assets | 0—0.0% | 0−100%0.0% | 0.1−80.0%0.3% | 0.2−66.7%0.6% | 0.3−57.2%0.8% | 0.4−50.0%0.8% | 0.5−44.5%1.4% | 0.6−40.0%1.9% | 0.7−48.3%2.4% | 0.8—3.7% | 0.9—2.8% | 1.1—3.3% | 1.4—5.2% | |
| Total assets | 28—100% | 28−47.6%100% | 39+0.7%100% | 34+3.9%100% | 40+31.7%100% | 53+135%100% | 39+13.4%100% | 33+2.3%100% | 31+12.6%100% | 23—100% | 34—100% | 32—100% | 27—100% | |
| Accounts payable | 1.0—3.6% | 1.0+34.9%3.6% | 0.7−19.9%1.7% | 1.1+29.9%3.2% | 1.0−21.8%2.4% | 0.8−33.8%1.4% | 0.8−7.8%2.2% | 0.8−14.4%2.5% | 1.2+8.3%4.0% | 1.1—5.0% | 0.9—2.6% | 1.0—3.0% | 1.1—4.2% | |
| Current liabilities | 22—77.7% | 22−17.4%77.7% | 28−6.5%70.7% | 29−19.6%86.2% | 29+21.5%70.7% | 26+83.9%49.3% | 29+84.1%76.1% | 37+83.1%112% | 24−19.9%76.6% | 14—63.1% | 16—46.8% | 20—62.3% | 29—108% | |
| Lease liabilities (non-current) | 0.3—1.0% | 0.3−75.9%1.0% | 0.5−63.6%1.3% | 0.7−56.6%2.0% | 0.9−48.5%2.3% | 1.2−42.5%2.2% | 1.4−35.8%3.6% | 1.6+806%4.9% | 1.8+805%5.9% | 2.0—8.9% | 2.2—6.3% | 0.2—0.6% | 0.2—0.7% | |
| Total liabilities | 22—78.7% | 22−19.9%78.7% | 28−9.1%71.9% | 30−21.2%88.3% | 30+16.5%73.0% | 27+68.3%51.4% | 31+69.9%79.7% | 38+89.4%116% | 25−14.4%82.4% | 16—72.0% | 18—53.2% | 20—62.9% | 30—108% | |
| Retained earnings | −319—−1146% | −319—−1146% | −313—−803% | −298—−874% | −274—−678% | −258—−485% | −248—−640% | −240—−731% | −204—−663% | −192—−851% | −180—−527% | −169—−527% | −151—−553% | |
| Shareholders' equity | 5.9—21.3% | 5.9−77.0%21.3% | 11+39.0%28.1% | 4.0—11.7% | 11+103%27.0% | 26+308%48.6% | 7.9−50.8%20.3% | −5.4−145%−16.4% | 5.4—17.6% | 6.3—28.0% | 16—46.8% | 12—37.1% | −2.3—−8.5% | |
| Total liabilities and equity | 28—100% | 28−47.6%100% | 39+0.7%100% | 34+3.9%100% | 40+31.7%100% | 53+135%100% | 39+13.4%100% | 33+2.3%100% | 31+12.6%100% | 23—100% | 34—100% | 32—100% | 27—100% | |
| Shares outstanding | 191—— | 191+45.9%— | 191+87.3%— | 165+95.4%— | 131+108%— | 131+154%— | 102+106%— | 84+80.5%— | 63+49.0%— | 52—— | 49—— | 47—— | 42—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.9−0.6%16.2% | 0.2*+2.3%18.7% | 0.2*+0.9%15.2% | 0.2+0.5%17.7% | 0.2*−5.9%13.9% | 0.2*+2.3%18.2% | 0.2*−3.1%19.1% | 0.2−55.9%26.7% | 0.2*−64.7%18.5% | 0.2*—18.3% | 0.2*—23.5% | 0.5—50.0% | 0.6*—60.5% | |
| Share-based compensation | 5.7+30.2%105% | 1.5+26.0%121% | 1.7+48.2%115% | 1.4+48.7%112% | 1.2*+1.4%77.5% | 1.2−6.2%95.1% | 1.1−4.8%98.3% | 0.9+27.7%115% | 1.1*+53.6%96.0% | 1.2—105% | 1.2—123% | 0.7—74.2% | 0.7*—71.9% | |
| Cash from operating activities | −52—−948% | −16*—−1293% | −11*—−766% | −12—−963% | −13*—−836% | −11*—−900% | −11*—−907% | −12—−1505% | −9.9*—−825% | −10*—−868% | −11*—−1176% | −13—−1260% | −10.0*—−960% | |
| Capital expenditure | −0.3—−5.6% | −0.0*—−1.4% | −0.0*—−1.4% | −0.2—−17.1% | −0.1*—−3.4% | −0.0*—−2.3% | −0.0*—−2.1% | −0.1—−11.2% | — | — | — | — | — | |
| Intangible assets bought | — | — | — | — | — | — | — | — | 0*—0.0% | — | — | — | — | |
| Cash from investing activities | −0.3—−5.6% | −0.0*—−1.4% | −0.0*—−1.4% | −0.2—−17.1% | −0.1*—−3.4% | −0.0*—−2.3% | −0.0*—−2.1% | −0.1—−11.2% | −0.3*—−21.6% | −0.4*—−29.9% | 0*—0.0% | −0.0—−3.7% | −0.2*—−16.8% | |
| Cash from financing activities | 22−70.8%414% | 0.2*−99.4%13.0% | 17*+2.4%1143% | 5.5−64.5%437% | 0.0*−100.0%0.1% | 27*+28762%2240% | 16*+41.5%1415% | 15−16.7%1864% | 18*+260%1504% | 0.1*—8.0% | 12*—1192% | 19—1850% | 5.0*—481% | |
| Change in cash | −29−189%−540% | −15*−195%−1281% | 5.5*−6.1%375% | −6.8−337%−544% | −13*−260%−840% | 16*—1338% | 5.9*+3797%506% | 2.9−51.0%348% | 7.9*—657% | −10*—−890% | 0.2*—15.5% | 5.9—587% | −5.2*—−496% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Lucid Diagnostics Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 1 · Auditor changed 1 · Directors and officers 1 · Material agreement 7 · Agreement ended 1 · New debt 2 · Unregistered share sale 3 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Unregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreementAgreement endedNew debtUnregistered share saleShareholder rights changed | 8-K | |
| Material agreementNew debtUnregistered share saleShareholder rights changed | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Product recalls by Lucid Diagnostics Inc.#
1 recalls since 2015, 220 units in the notices that give a number. Medical devices (FDA): 1.
| Date | What and why | Units | Notice |
|---|---|---|---|
| Brand Name: EsophaCap Product Name: EsophaCap (25mm diameter, 10 pores/inch) Model/Catalog Number: EC25T10VI Software Version: N/A Product Description: EsophaCap is pouched as individual units. 10 units go into a shelf-box. Component: N/A (and 1 more products)The EsophaCap sponge may be at increased risk of detaching from the string during removal of the device from the patient, particularly at the lower esophageal sphincter at the gastroesophageal junction or the upper esophageal sphincter between the pharynx and the esophagus, which is the narrowest part of the alimentary canal.Medical devicesClass II | 220 | Z-1900-2024 |
Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness
How Lucid Diagnostics Inc. compares in Healthcare
- Market cap$89 M · higher than 25% of 2,013
- Revenue$5 M · higher than 18% of 1,795
- Net margin-892.3% · higher than 1% of 1,485
- Revenue growth8.3% · higher than 50% of 1,003
- Price / sales16.4× · lower than 15% of 1,071
- Price / book8.1× · lower than 18% of 1,245
- FCF yield-52.5% · higher than 17% of 835
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Lucid Diagnostics Inc.🇺🇸 | $89 M | — | -892.3% | +8.3% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of March 23, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Lucid Diagnostics Inc.? Verify and update this profile — free
Show Lucid Diagnostics Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.